Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Azithromycin can also be used to treat other conditions, such as sinusitis, pneumonia, bronchitis, sinusitis, otitis media, acute bronchitis, tonsillitis, chronic sinusitis, tonsillitis, otitis media, and chronic bronchitis. If you take Vernon Hills kamagra jelly online uk zithromax for a long time, you may need to take the medication with food, so you may experience some stomach upset. Amoxicillin and the β-lactam β-lactam penicillin are very similar to the naturally occurring penicillin and are closely related to it structurally.

I had been prescribed the medication, but i couldnt find any information regarding generic nolvadex in india, and no one seemed to know what i was supposed to do. The condition is characterised cytotec 200 mg kaufen by recurrent nephritic-range proteinuria without systemic disease, and can be caused by a number of renal disorders, including nephritic syndrome after acute infection, glomerulonephritis, and autoimmune glomerulonephritis. These findings suggest that amoxicillin can be an important antibiotic for clinical use as a protector against oxidative stress-induced cell death.

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 32
Format: PDF
Product Line: Brief Report
Product Code: LMBR0017
Release Date: May of 2022

Cadherins are a family of glycoproteins responsible for calcium ion–dependent cell adhesion. There are more than 100 types of cadherins in humans, and many of them are not only responsible for cell adhesion but also involved in tumorigenesis. Cadherin 17 (CDH17), also known as human liver intestine–cadherin (LI-cadherin), or intestinal human peptide transporter-1 (HPT-1), is a non-classical cadherin composed of an ectodomain consisting of seven extracellular cadherin (EC) repeats, a single transmembrane domain, and a short cytoplasmic domain.

CDH17 is a highly specific marker of gastrointestinal epithelium; most gastrointestinal adenocarcinomas are CDH17-positive with strong membranous staining. However, healthy tissue colonic mucosa and duodenal mucosa also are positive for CDH17 which prevented consideration of CDH17 as an ideal tumor associated antigen for development of CDH17-targeted therapies.

It was only very recently, that investigators discovered that CDH17 is masked in healthy tissue and is not attacked by large molecules or cells. Thus, CDH17 represents a class of previously unappreciated tumor-associated antigens that is ‘masked’ in healthy tissues from attack by CAR T cells for developing safer cancer immunotherapy.

This report describes and analyzes as of May 2022

  • The scientific rationale for CDH17-targeted therapies based on target characteristics and its differential expression profile;
  • Preclinical proof-of-concept of CDH17-targeted different drug modalities;
  • Clinical indications suitable for development of CDH17-targeted therapies and their patient populations;
  • The competitive landscape of CDH17-targeted drug modalities in development;
  • Specific profiles of CDH17-targeted drug modalities; and
  • Profiles of companies active in the development of anti-CDH17 therapy candidates.

Effector-enhanced antibodies and cells such as antibody-drug conjugates, chimeric antigen receptor (CAR) T-cells, and bispecific antibodies redirecting T-cells or specifically activating T-cells will be enabled by and benefit from the cancer “selective” expression profile to avoid on-target, off-tumor toxicity.

CDH17 provides a great opportunity for drug discovery and development as the competitive landscape still is very favorable for new entrants, but the first molecules have entered clinical development.

Table of Contents

1          Target Background

2          Target Antigen Expression Profile

3          Preclinical Proof-of-Concept

4          Clinical Indications & Patient Populations

5          Competitive Landscape & Drug Modalities

6          Drug & Cell Therapy Candidate Profiles

6.1       CAR T-Cells

6.2       Pro-Apoptotic Bispecific Antibodies

6.3       T-Cell Redirecting Bispecific Antibodies

6.4       Naked Antibodies

7          Company Profiles

8          References

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01